Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257257 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 281
- Enrollment target
NCT00257257 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 281 participants.
The verdict
NCT00257257, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 281 participants
- Enrollment target
Study Summary
Primary: Effect on HbA1c over 6 months in drug-naive patients with type 2 diabetes Secondary: Effect on glucose, insulin, C-peptide, insulin resistance, body weight, HDL-cholesterol, triglycerides, blood pressure - Safety, tolerability
Interventions
- DRUG Rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257257
The ClinicalTrials.gov registry entry for NCT00257257 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimonabant (SR141716) is the first listed.
NCT00257257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257257 about?
NCT00257257 is a clinical study titled "Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients". Primary: Effect on HbA1c over 6 months in drug-naive patients with type 2 diabetes Secondary: Effect on glucose, insulin, C-peptide, insulin resistance, body weight, HDL-cholesterol, triglycerides, blood pressure - Safety, tolerability
What is the current status of trial NCT00257257?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2005-03. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00257257?
The interventions under investigation include: Rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00257257?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.